TITAN PHARMACEUTICALS INC (TTNP)

Company Profile

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California and currently employs 4 full-time employees. The firm is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Company Info

TITAN PHARMACEUTICALS INC

Suite 505, 400 Oyster Point Blvd

San Francisco CALIFORNIA 94080

P: 14152444990

CEO: Marc Rubin

Employees: 4

Website: https://www.titanpharm.com/